Dean J. Kereiakes,
MD
Chairman
Medical Director
The Lindner Center for Research and Education
Chief Executive Officer and Director of Research
The Ohio Heart Health Center
Cincinnati, Ohio, United States
Professor of Clinical Medicine
Ohio State University
Columbus, Ohio, United States
Elliott M. Antman,
MD
Professor of Medicine
Harvard Medical School
Director, Samuel A. Levine Cardiac Unit
Brigham and Women’s Hospital
Boston, Massachusetts, United States
Gilles Montalescot,
MD, PhD
Professor
Hôpital la Pitié-Salpétrière
lnstitut du Coeur
Paris, France
Eric J. Topol, MD
Provost and Chief Academic Officer
Chairman, Department of Cardiovascular Medicine
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
James T. Willerson,
MD
President
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Bios
Dr. Kereiakes is medical director at the Carl and Edyth Lindner Center for Research and Education in Cincinnati, Ohio, chief executive officer and director of research at The Ohio Heart Health Center in Cincinnati, and professor of clinical medicine at Ohio State University in Columbus. He received his MD from the University of Cincinnati. His postgraduate training included an internship and residency at the University of California, San Francisco, a senior residency at Massachusetts General Hospital in Boston, and a chief residency at the University of California, San Francisco. He was a fellow in adult cardiology at the University of California, San Francisco, and in coronary angioplasty at the San Francisco Heart Institute and Sequoia Hospital. Dr. Kereiakes has been an investigator for most of the interventional technologies introduced in the last decade and has performed more than 20,000 catheterization laboratory procedures.
Dr. Kereiakes is a fellow of the American College of Cardiology (ACC) and a member of the American Heart Association (AHA) Committee on Cardiac Catheterization and Intervention. He was a member of the Joint ACC/AHA Task Force Committees that wrote guidelines for both coronary angioplasty and unstable angina. Dr. Kereiakes was selected as an outstanding alumnus of the University of Cincinnati School of Medicine. He was also named in Who’s Who in America, Who’s Who in Medicine and Healthcare, and Best Doctors in America, and received the Cincinnati Business Courier Health Care Hero-Innovator award and the Ohio Valley AHA’s Kaplan Visionary Award for cardiovascular research.
In addition to lecturing nationally and internationally, Dr. Kereiakes is active as a clinical and scientific investigator and has participated in more than 500 clinical research protocols. He has published more than 400 journal articles, abstracts, and book chapters. He serves on the editorial boards of the American Heart Journal, The Journal of Invasive Cardiology, the American Journal of Cardiology, and Circulation, and is a section editor for both Circulation (Expert Opinions) and MedReviews (New Drugs and Devices).
Disclosure
Dr. Kereiakes does not have a significant relationship with any commercial entity that may represent, in perception or reality, a conflict of interest in the context of his presentation. Presentation will not include discussion of off-label/unapproved uses of drugs or devices.
Dr. Antman is director of the Samuel A. Levine Cardiac Unit in the Cardiovascular Division of the Brigham and Women’s Hospital in Boston, Massachusetts. He received his MD from the Columbia University College of Physicians and Surgeons and served as resident in internal medicine at Columbia Presbyterian Medical Center. After completing his cardiology fellowship at the Peter Bent Brigham Hospital, he joined the faculty of Harvard Medical School where he is now a professor of medicine.
Dr. Antman has published widely on cardiovascular pharmacology and electrophysiology. He is a senior investigator in the TIMI research program and was the principal investigator for the TIMI 9, TIMI 11, TIMI 14, and ENTIRE-TIMI 23 trials dealing with new treatments for acute coronary syndromes. He is now the principal investigator for ExTRACT-TIMI 25, comparing enoxaparin with unfractionated heparin for ST-elevation myocardial infarction patients receiving fibrinolysis. In addition, Dr. Antman has published on the use of serum cardiac markers for diagnosis and prognosis of patients with unstable angina and acute myocardial infarction. As an outgrowth of a major interest in meta-analysis of randomized trials of cardiovascular therapies, he was the chair of the steering committee for the Magnesium in Coronaries (MAGIC) study, sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health.
Dr. Antman has been an active member of several American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines Committees, and is the chairman of the ACC/AHA Committee to Revise the Guideline for Management of ST-elevation Myocardial Infarction. In 2001, he was named the vice chairman of the overall ACC/AHA Task Force on Practice Guidelines and became its chairman in 2003. He is also a member of the AHA Clinical Cardiology Program Committee, of the AHA Science Advisory and Coordinating Committee, and of the ACC Quality Strategic Oversight Committee. He is the recipient of the Gifted Teacher Award of the ACC (2003).
Disclosure
Grant/research support — Eli Lilly and Company. Presentation will include discussion of the off-label/unapproved use of clopidogrel in stenting.
Professor Montalescot is professor of cardiology and head of the Intensive Cardiology Care Unit at Hôpital la Pitié-Salpétrière in Paris, France. He earned his MD at Université Paris XII in 1987 and was a fellow at Massachusetts General Hospital in Boston from 1987 – 1988.
He has extensive experience in basic and clinical research and is a regular adviser for research committees including the French Ministry of Research and Education. He has served on several task forces on antithrombotic drugs and acute coronary syndromes. His main expertise is in the field of coronary thrombosis, ranging from pathogenesis to therapeutics. Professor Montalescot has been an investigator for many antithrombotic drugs developed in the past 10 years, as well as for many new interventional technologies. He has been the principal investigator of several randomized trials including ADMIRAL and ARMADA. Professor Montalescot is an active member of a number of organizations with a major interest in education and research in thromboembolic diseases. He was chairman of the Working Group on Thrombosis of the French Society of Cardiology and is a member of the nucleus of the Working Group on Thrombosis and Platelets of the European Society of Cardiology.
Professor Montalescot is the recipient of several awards in France including the J. Valade Prize from the Fondation de France and the J. Escalle Award from the National Academy of Medicine. He has published many peer-reviewed articles in such journals as The New England Journal of Medicine and Circulation, and has delivered many invited international lectures.
Disclosure
Prof. Montalescot does not have a significant relationship with any commercial entity that may represent, in perception or reality, a conflict of interest in the context of his presentation. Presentation will not include discussion of off-label/unapproved uses of drugs or devices.
Dr. Topol is chief academic officer of The Cleveland Clinic Foundation and provost of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Ohio. He is also chairman of the Department of Cardiovascular Medicine and professor of medicine.
Dr. Topol is a member of the American Association of Physicians, the American Society of Clinical Investigation, and the Johns Hopkins Society of Scholars. He is a fellow of the American College of Cardiology, American College of Physicians, and European Society of Cardiology.
He has been recognized by the Institute of Scientific Information to be among the top 10 cited biomedical researchers (1993 – 2003), and has been ranked first by Science Watch among authors of high-impact papers in cardiovascular research (1993 – 2000). His work on the genomics of coronary disease led to the discovery of the first mutation (MEF2A deletion) inducing coronary disease and heart attack, was ranked as a top-10 research advance by the American Heart Association, and earned him the Clinical Research Innovator Award of the Doris Duke Charitable Foundation in 2001. The program he directs in Cleveland has been ranked number 1 in the United States by U.S. News & World Report for the past 9 years.
Dr. Topol has served as chairman and principal investigator for more than 15 international, multicenter, randomized clinical trials, including the five GUSTO trials, the largest heart attack studies ever conducted, and many others, with cumulatively more than 200,000 patients enrolled. He was the first physician to administer recombinant tissue plasminogen activator, two different platelet GP IIb/IIIa inhibitors (abciximab and eptifibatide), and a novel anticoagulant (bivalirudin) to patients with coronary artery disease. The results of these large-scale trials, involving 40 countries, have substantially changed the approach to patients with acute myocardial infarction, percutaneous coronary intervention, and unstable angina.
He is on the editorial board for more than 20 peer review medical publications including Circulation (consulting editor), Circulation Research, Journal of the American College of Cardiology, American Journal of Cardiology, Heart, and European Heart Journal. Dr. Topol has more than 850 original publications and has edited 16 books, including the Textbook of Interventional Cardiology (first – fourth editions) and the Textbook of Cardiovascular Medicine, now in its second edition.
Disclosure
Consultant — Eli Lilly and Company. Presentation will not include discussion of off-label/unapproved uses of drugs or devices.
Dr. Willerson is president of the University of Texas Health Science Center at Houston and is the Alkek-Williams Distinguished Professor. He holds the Edward Randall III Chair in Internal Medicine at the University of Texas Health Science Center at Houston, the Dunn Chair in Cardiology Research at the Texas Heart Institute, and the Robert J. Hall Chair of Cardiology at St. Luke’s Episcopal Hospital. He also serves as the medical director, chief of cardiology, director of cardiology research, and codirector of the Cullen Cardiovascular Research Laboratories at the Texas Heart Institute, and chief of cardiology at St. Luke’s Episcopal Hospital. In addition, he is an adjunct professor of medicine at Baylor College of Medicine and at the University of Texas M.D. Anderson Cancer Center in Houston. Previously, Dr. Willerson was professor of medicine and director of the cardiology division at the University of Texas Southwestern Medical School in Dallas and director and principal investigator of the National Heart, Lung, and Blood Institute’s Specialized Center of Research. Upon his departure from the University of Texas Southwestern Medical School, the James T. Willerson, MD, Distinguished Chair in Cardiovascular Diseases was established. From 1989 through 2000, he was the chairman of the Department of Internal Medicine at the University of Texas Medical School at Houston where an annual lectureship has been established in his name.
Dr. Willerson is a Phi Beta Kappa graduate of the University of Texas at Austin. Upon graduation from Baylor College of Medicine, he completed his medical and cardiology training at Massachusetts General Hospital in Boston and at the National Institutes of Health (NIH) in Bethesda, Maryland.
He is the former chairman of the American Heart Association (AHA) Research Committee and of the NIH Cardiovascular and Renal Study Section. He received the Award of Merit from the AHA and served as a member of the board of directors and steering committee of the AHA.
Dr. Willerson served as visiting professor and invited lecturer at more than 200 institutions worldwide. He is the recipient of many national and international awards, including the James B. Herrick Award from the AHA, the American College of Cardiology’s Distinguished Scientist Award, the Distinguished Achievement Award from the Scientific Councils of the AHA, and the AHA’s Distinguished Scientist Award. He is a fellow in the Royal Society of Medicine of the United Kingdom and an honorary member of the Society of Cardiology of Peru, the Society of Cardiology of Spain, the Hellenic Society of Cardiology of Greece, and the Society of Cardiology of Venezuela. He is a member and past president of the Paul Dudley White Cardiology Society at Harvard Medical School and Massachusetts General Hospital.
He is a member of the American Society of Clinical Investigation, the Association of American Physicians, the Association of Professors of Medicine, and the Institute of Medicine of the National Academy of Sciences. He was named a distinguished alumnus by Baylor College of Medicine and by the University of Texas at Austin.
In 1989, Dr. Willerson created the Institute of Molecular Medicine for the Prevention of Human Diseases, a clinical research effort devoted to the discovery of genes that cause the human diseases of our time. He also founded TexGen Research, a collaboration which brings together the institutions in the Texas Medical Center to collect information about genes that play a key role in causing major diseases.
He has served on many editorial boards for professional publications including The New England Journal of Medicine, Journal of Clinical Investigation, Circulation Research, Arteriosclerosis and Thrombosis, American Journal of Medicine, Journal of the American College of Cardiology, American Journal of Cardiology, American Heart Journal, and Cardiovascular Medicine. Since 1993, he has been the editor of Circulation. He has edited or co-edited 20 textbooks, including the second edition of Cardiovascular Medicine, and has published more than 770 scientific articles.
Disclosure
Dr. Willerson does not have a significant relationship with any commercial entity that may represent, in perception or reality, a conflict of interest in the context of his presentation. Presentation will not include discussion of off-label/unapproved uses of drugs or devices.
For technical support, call 1-877-893-6808, or send an email to support@vioworks.com